Tysabri Related Published Studies
Well-designed clinical trials related to Tysabri (Natalizumab)
Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab
in relapsing MS. [2012]
Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. [2011.04]
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. [2010.05.15]
Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. [2010.02]
Multiple sclerosis associated fatigue during natalizumab treatment. [2009.10.15]
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. [2009.03]
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. [2009.03]
Cost-Effectiveness Analyses of Natalizumab (Tysabri((R))) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK. [2008]
Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. [2007.12]
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. [2007.10.02]
Health-related quality of life in multiple sclerosis: effects of natalizumab. [2007.10]
Expert opinion: Guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. [2007.07]
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. [2007.05]
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. [2007.04.24]
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. [2007.04.17]
A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis. [2007.03]
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. [2007.01]
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. [2006.03.02]
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. [2006.03.02]
Natalizumab induction and maintenance therapy for Crohn's disease. [2005.11.03]
Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. [2005.10]
Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. [2004.06.08]
Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. [2004.04]
Is natalizumab a breakthrough in the treatment of multiple sclerosis? [2003.06]
Natalizumab for active Crohn's disease. [2003.01.02]
A controlled trial of natalizumab for relapsing multiple sclerosis. [2003.01.02]
A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. [1999.03.23]
Well-designed clinical trials possibly related to Tysabri (Natalizumab)
Pharmacological treatment for memory disorder in multiple sclerosis. [2013]
PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of
relapsing multiple sclerosis. [2010]
GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. [2009.03.03]
Monoclonal antibodies in the therapy of multiple sclerosis: an overview. [2008.12]
Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment. [2008]
Newer Therapies for Inflammatory Bowel Disease. [2004.06]
A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. [2001.08]
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. [1999.08.11]
Other research related to Tysabri (Natalizumab)
Natalizumab treatment shows no clinically meaningful effects on immunization
responses in patients with relapsing-remitting multiple sclerosis. [2014]
Natalizumab: bench to bedside and beyond. [2013]
Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. [2011.11.07]
Natalizumab for relapsing remitting multiple sclerosis. [2011.10.05]
Immune reconstitution inflammatory syndrome in natalizumab-associated PML. [2011.09.13]
Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. [2011.08.09]
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. [2011.08]
Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. [2011.07.15]
Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. [2011.06]
Natalizumab and HSV meningitis. [2011.06]
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. [2011.06]
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. [2011.05.31]
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. [2011.05.17]
The toronto observational study of natalizumab in multiple sclerosis. [2011.05]
Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells. [2011.05]
[Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?]. [2011.04]
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society. [2011.04]
[An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis]. [2011.03.16]
Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months. [2011.03]
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. [2011.01]
Efficacy of natalizumab therapy in patients of African descent with relapsing
multiple sclerosis: analysis of AFFIRM and SENTINEL data. [2011]
Safety and efficacy of natalizumab in children with multiple sclerosis. [2010.09.07]
Natalizumab dosage suspension: are we helping or hurting? [2010.09]
JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. [2010.09]
Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. [2010.09]
Natalizumab drug holiday in multiple sclerosis: poorly tolerated. [2010.09]
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? [2010.08]
Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. [2010.07]
Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. [2010.06.10]
Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy. [2010.06]
A giant MS plaque mimicking PML during natalizumab treatment. [2010.04.15]
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. [2010.04]
Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. [2010.03]
Natalizumab for the treatment of Crohn's disease. [2010]
Progressive multifocal leukoencephalopathy after natalizumab monotherapy. [2009.09.10]
Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. [2009.09.10]
Asymptomatic reactivation of JC virus in patients treated with natalizumab. [2009.09.10]
Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy. [2009.09]
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. [2009.08]
Natalizumab in the treatment of multiple sclerosis. [2009.06]
Immunotoxicity profile of natalizumab. [2009.06]
Effects of natalizumab, an alpha4 integrin inhibitor, on the development of Hartley guinea pigs. [2009.04]
The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. [2009.04]
Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. [2009.03]
Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. [2009.03]
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. [2009.02.03]
alpha4-Integrin antagonism with natalizumab: effects and adverse effects. [2008.12]
Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. [2008.10.21]
Effects of natalizumab treatment on Foxp3+ T regulatory cells. [2008.10.06]
Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. [2008.09.02]
Natalizumab: a country-based surveillance program. [2008.09]
Early relapses after the first dose of natalizumab in active multiple sclerosis patients. [2008.09]
Quantitative risk-benefit analysis of natalizumab. [2008.07.29]
Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. [2008.06]
Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy. [2008.06]
[Open use of natalizumab. Neutralising antibodies and clinical data] [2008.06]
Allergic and nonallergic delayed infusion reactions during natalizumab therapy. [2008.05]
Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. [2008.04.30]
The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. [2008.04.01]
Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. [2008.04.01]
[New drugs; natalizumab] [2008.03.01]
Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis. [2008.03]
Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. [2008.02]
[Natalizumab in multiple sclerosis: the second treatment revolution] [2008.01]
Natalizumab: targeting alpha4-integrins in multiple sclerosis. [2008]
Multiple sclerosis and Natalizumab. [2007.11]
|
